<DOC>
	<DOCNO>NCT01256593</DOCNO>
	<brief_summary>The objective Investigation evaluate safety efficacy Lyrica medical practice . Also , occurrence unknown known adverse drug reaction ( ADRs ) subject treat Lyrica monitor survey period , whether additional treatment outcome investigation and/or post-marketing clinical study require future determine .</brief_summary>
	<brief_title>Safety And Efficacy Of Lyrica ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All patient investigator prescribes first Lyrica® register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients need administer Lyrica® order enrol surveillance . Patients administer Lyrica® .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lyrica</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
	<keyword>Safety</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>